Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.

<bold>Background: </bold>The objective of this study was to analyze the impact of visceral metastases in castration-resistant prostate cancer (CRPC) treated with abiraterone.<bold>Materials& Methods: </bold>All CRPC patients received abiraterone 1000 mg daily plus prednisone 10 mg orally daily. Liver and lung metastases were considered as visceral metastases.<bold>Results: </bold>Of 265 CRPC patients, 49 had visceral metastases. Results on progression-free survival were not significantly different in patients with or without visceral metastases. Conversely, the median overall survival between the two groups was 12.4 and 18.5 months (p = 0.01), respectively, and median overall survival of patients with liver-only disease versus other sites was 10.5 versus 18.5 months (p = 0.006), respectively.<bold>Conclusion: </bold>Visceral disease appears to be an important predictor of clinical outcome in CRPC patients treated with abiraterone. [ABSTRACT FROM AUTHOR]